The Billion-Dollar Biotech
June 3, 2015
Moderna Therapeutics has big ambitions and a bankroll to match. How a fledgling start-up became one of the most highly valued private drug firms ever.
Continue reading at Nature.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.